What is in clinical development for Bundibugyo and Sudan virus. None of these candidates is approved for use. Tracker only; not a guide to clinical availability.
Last updated
Important
Nothing on this page is an approved medical product.
Every candidate listed here is investigational. Some are in clinical trials; some are pre-clinical; one or two are stockpiled for emergency-use authorisation under WHO R&D Blueprint protocols. None can be requested or purchased as a routine clinical product. The approved Ebola vaccines and antibody treatments cover Zaire ebolavirus only. This page exists to give journalists, public-health staff, and researchers a current snapshot of the pipeline, not as clinical guidance.
This is editorial reference, not medical advice. If you may have been exposed to Ebola, contact your local public-health authority.
Bundibugyo virus (BDBV) candidates
The strain behind the active 2026 PHEIC. The pipeline is thinner than for Zaire or Sudan, partly because Bundibugyo has caused only three recognised outbreaks before 2026.
cAd3-BDBV (BDBV-specific candidate)
Pre-clinicalvaccineNot approved
NIAID Vaccine Research Center · Targets BDBV
Mechanism. Chimpanzee adenovirus type 3 vector encoding the Bundibugyo virus glycoprotein. The platform mirrors cAd3-EBO Z (Zaire) and cAd3-EBO S (Sudan).
Where it stands. Reported in pre-clinical animal studies. No human trials of a BDBV-specific cAd3 candidate are listed on ClinicalTrials.gov as of May 2026. Filovirus glycoprotein cross-reactivity may permit Phase 1 acceleration if WHO declares emergency-use scientific priority.
Oxford Vaccine Group + Serum Institute of India · Targets BDBV
Mechanism. Chimpanzee adenovirus (ChAdOx1) vector expressing the Bundibugyo virus glycoprotein. Same platform as the Oxford-AstraZeneca COVID-19 vaccine; designed as a monovalent BDBV-specific candidate.
Where it stands. In two Phase 1 trials of safety and immune response, in Oxford since July and in Masaka, Uganda, since 6 October 2026; neither tests whether it prevents disease. On 4 November WHO advisers recommended adding it to the Tumaini trial in DRC once national approvals are in place. No vaccine is approved against Bundibugyo virus.
Timeline
WHO's Technical Advisory Group on Candidate Vaccines Prioritization recommended the candidate for further clinical evaluation in Tumaini, the Phase 2/3 ring-vaccination trial in DRC, on the basis of preclinical and early clinical evidence. It enters the trial once national approvals are in place. It is recommended together with Moderna's mRNA-1469; WHO says this will be the first evaluation of a Bundibugyo-specific vaccine during an outbreak of the disease.
Tumaini (NCT07842107) enrolled its first participants in Bunia, starting with the Zaire-licensed Ervebo.
CEPI named it as one of two Bundibugyo-specific vaccines due to join Tumaini, and WHO's immunisation director said it could join quickly if its early safety and immune-response data are positive.
Earlier milestones and background (9 more)Show less
A second Phase I study began in Uganda: the MRC/UVRI and LSHTM Uganda Research Unit vaccinated its first participants in Masaka City, with the University of Oxford as sponsor, CEPI as funder and about 3,000 investigational doses from the Serum Institute of India. Like the UK trial, it measures safety and immune response in healthy adults, not protection.
BD-Ebov vaccinated its first volunteer, the first time ChAdOx1 BDBV was given to a human; further volunteers were enrolled and dosed over the following weeks.
The Oxford Vaccine Group launched BD-Ebov, the world's first Phase 1 trial of a vaccine candidate against Bundibugyo virus, in 50 healthy adults aged 18-55 in Oxford, with 4,000 investigational doses from the Serum Institute of India. Chief investigator: Professor Katrina Pollock; lead scientific investigator: Professor Teresa Lambe, both of the Oxford Vaccine Group and Pandemic Sciences Institute.
CEPI committed up to US$8.6 million towards preclinical testing and preparation for Phase 1.
A WHO expert consultation endorsed the candidate for trial evaluation pending further animal data, advising a single-dose approach for contacts of cases and a two-dose approach for high-risk unexposed groups such as health workers.
Announced in response to the DRC and Uganda PHEIC, with no animal or human studies completed at that point and trial doses then estimated two to three months away.
The Serum Institute of India manufactured and stockpiled approximately 620,000 doses of the candidate within two weeks for potential later-stage trials and emergency use.
If the early studies succeed, CEPI expects to support late-stage trials with Oxford and the Serum Institute of India.
The vaccine was developed at Oxford's Vaccine Group and Pandemic Sciences Institute. The Phase 1 trials measure safety and immune response, not efficacy.
Mechanism. Lipid-nanoparticle-encapsulated messenger RNA encoding the Bundibugyo virus glycoprotein. Same mRNA platform validated during COVID-19, applied to a novel filovirus target.
Where it stands. In a Phase 1 trial of safety and immune response in Canada since 3 August 2026, with about 80 healthy adults; a Phase Ib trial in Uganda was approved on 7 October but no enrolment has been reported. On 4 November WHO advisers recommended adding it to the Tumaini trial in DRC once national approvals are in place. No efficacy data exists.
Timeline
WHO's Technical Advisory Group on Candidate Vaccines Prioritization recommended the candidate for further clinical evaluation in Tumaini, the Phase 2/3 ring-vaccination trial in DRC, on the basis of preclinical and early clinical evidence. It enters the trial once national approvals are in place. It is recommended together with Oxford's ChAdOx1 BDBV.
Tumaini (NCT07842107) enrolled its first participants in Bunia, starting with the Zaire-licensed Ervebo.
CEPI named it as one of two Bundibugyo-specific candidates due to join Tumaini as it becomes available.
Earlier milestones and background (4 more)Show less
The candidate received ethical approval for a Phase Ib trial in Uganda, Africa CDC said on 8 October; no first enrolment there has been reported.
The first participant was dosed in Truro, Nova Scotia, in a first-in-human Phase 1 trial at three sites in Canada under Health Canada authorisation. It aims to enrol about 80 healthy adults and measures safety, tolerability and immune response, not efficacy.
CEPI committed up to US$50 million for preclinical testing, the Phase 1 trial and scaled manufacture of trial doses.
Moderna says it would supply at least 500,000 doses to low- and middle-income countries if the vaccine is licensed.
Mechanism. Recombinant vesicular stomatitis virus vector engineered to express the Bundibugyo glycoprotein. Same rVSV platform underlying Merck Ervebo (which targets Zaire only) and the WHO-prequalified Zaire vaccine.
Where it stands. Preclinical: the single-dose candidate has protected nonhuman primates but has not yet been tested in humans. On 28 October 2026 BARDA awarded IAVI US$36 million, under a contract worth up to US$99 million, for doses and a Phase 1 trial, with a ring-vaccination trial in DRC as the stated next step. No dose is deployed outside trials.
Timeline
IAVI said the US Biomedical Advanced Research and Development Authority (BARDA) awarded it US$36 million under a contract worth up to US$99 million to manufacture doses for clinical evaluation and outbreak response, run a Phase 1 trial and develop an updated candidate matched to the 2026 outbreak variant. Manufacturing partners are Hilleman Laboratories, SK bioscience and its subsidiary IDT Biologika.
WHO's Director-General said two vaccines designed specifically against Bundibugyo virus had entered human trials and that a separate vaccine showing cross-protection in animal studies was moving toward a Phase 3 trial.
CEPI announced up to US$8.5 million for Hilleman Laboratories, a Singapore-based joint venture of MSD and Wellcome, to develop and manufacture rVSV-platform Bundibugyo vaccine doses for clinical trials from master virus seed material generated by IAVI with CEPI funding, with MSD as technical adviser.
Earlier milestones and background (3 more)Show less
CEPI committed up to US$3.2 million towards its development.
WHO has identified the single-dose IAVI rVSV-BDBV candidate as the most promising vaccine in development, though it was estimated to be seven to nine months from human efficacy trials.
If early trials succeed, technology transfer to a large-scale manufacturer is planned to enable affordable supply in outbreak-affected countries.
Mechanism. Oral nucleotide analogue prodrug related to remdesivir, with broad pan-filovirus activity in pre-clinical models.
Where it stands. Tested since 14 July 2026 in EBO-PEP, a Phase 3 placebo-controlled trial and the first of post-exposure prophylaxis against Bundibugyo virus, in nearly 1,000 symptom-free contacts aged over 12 in Ituri, run by ALIMA with INRB and ANRS MIE. Gilead has licensed three generic makers to prepare supply. No Bundibugyo-specific human efficacy data exists yet.
Timeline
Gilead signed royalty-free voluntary licences with Dr. Reddy's Laboratories, Eva Pharma and Ferozsons Laboratories covering 127 mainly low- and lower-middle-income countries, so the drug can be made and supplied if trial data and regulatory approvals support it.
Recruitment opened in Ituri for EBO-PEP. The first PEP centres are adjacent to the ALIMA-run Ebola treatment centres in Bunia and Rwampara.
A WHO expert consultation reaffirmed obeldesivir as a priority candidate, while noting that contact-tracing difficulties complicate implementation.
Earlier milestones and background (7 more)Show less
WHO announced at its Virtual Ministerial Briefing that it would evaluate obeldesivir as post-exposure prophylaxis jointly with Africa CDC.
The ANRS researcher sheet describes EBO-PEP (ANRS 0515s) as a multicentre, multi-epidemic, phase III, comparative, adaptive trial; its obeldesivir sub-protocol is double-blind and placebo-controlled, measuring whether the drug prevents symptomatic Bundibugyo virus disease after high-risk exposure.
Participants had direct contact with a confirmed case within the previous five days, whether with a symptomatic patient, a corpse or a needlestick from a contaminated syringe, and are symptom-free at enrolment. They are monitored daily for 21 days, with a final visit at day 42.
EBO-PEP is coordinated by ALIMA with DRC’s INRB and France’s ANRS Emerging Infectious Diseases, with Médecins Sans Frontières ground support and Africa CDC study coordination. Principal investigators are Professor Pauline Byakika-Kibwika (Mbarara University of Science and Technology), Dr Marie Jaspard (Saint-Antoine Hospital / Inserm) and Professor Placide Mbala (INRB).
Funding is EUR 3.4 million from the Global Health EDCTP3 partnership, US$1 million from Africa CDC and US$5 million combined from DRC and South Africa.
A secondary protocol offers compassionate-use remdesivir to children under 12 and to pregnant or breastfeeding women, who are excluded from the obeldesivir arm.
EBO-PEP is designed as a platform intended to extend across sub-Saharan Africa; a Uganda arm has been announced, with no first enrolment confirmed there. An oral route simplifies field deployment compared with existing monoclonal antibody products.
Mechanism. Monoclonal antibody products approved as Ebanga (mAb114, ansuvimab) and Inmazeb (REGN-EB3) for Zaire ebolavirus. Pre-clinical cross-reactivity work has examined activity against BDBV glycoprotein with mixed results.
Where it stands. Neither product is approved for Bundibugyo virus; both are licensed for Zaire ebolavirus only. Some in-vitro and animal studies have observed cross-strain neutralisation. On 4 November 2026 WHO said maftivimab, one of Inmazeb's three antibodies, will soon be added to the PARTNERS treatment trial in DRC.
Timeline
WHO said maftivimab, one of Inmazeb's three antibodies, will soon be added to the PARTNERS treatment trial in DRC.
Background (1 more)Show less
The regulatory and clinical path to an expanded indication remains slow. Emergency-use protocols during a PHEIC could permit off-label evaluation under research authorisation.
Mapp Biopharmaceutical and Adimab, with USAMRIID and academic partners · Targets EBOV, SUDV, BDBV
Mechanism. Two-antibody cocktail engineered for broad pan-ebolavirus neutralisation. Unlike Inmazeb and Ebanga, which target Zaire ebolavirus only, MBP134 has shown protection against Zaire, Sudan, and Bundibugyo viruses in non-human primate challenge studies.
Where it stands. Tested in PARTNERS, the first clinical trial of treatments for Bundibugyo virus disease, which began in Bunia on 2 July 2026 and compares MBP134, remdesivir and both against standard care. WHO said on 4 November that initial findings are expected in the coming months. No Bundibugyo-specific efficacy data exists in humans yet.
Timeline
WHO said maftivimab, one of the three antibodies in the Zaire-licensed Inmazeb, will soon be added to the trial, and that initial findings from the treatment trials are expected in the coming months.
WHO's Director-General reported that the trial had enrolled 100 patients across three facilities in Ituri, against its 700 to 1,000 target.
PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) enrolled its first patient in Bunia.
Background (2 more)Show less
The trial is WHO-sponsored and coordinated by the Congolese INRB, the Institute of Tropical Medicine in Antwerp and the University of Oxford. It randomises patients of any age with confirmed disease to standard care alone, standard care plus MBP134, standard care plus remdesivir, or both drugs plus standard care, with mortality at 28 days as the primary endpoint and a target of 700 to 1,000 participants over six months.
A first-in-human Phase 1 trial of MBP134 had previously been conducted.
SUDV has caused recurring outbreaks since 1976. Two distinct candidate vaccines reached Phase 2 immunogenicity readouts before the 2022 Uganda Mubende outbreak. Both were prepared for emergency deployment; neither reached randomised efficacy data because the outbreak resolved before trials could enrol.
cAd3-EBO S
Phase 2vaccineNot approved
Sabin Vaccine Institute, NIAID, with academic partners · Targets SUDV
Mechanism. Chimpanzee adenovirus type 3 (cAd3) vector encoding the Sudan ebolavirus glycoprotein. Single-dose intramuscular regimen under investigation.
Where it stands. Phase 2 immunogenicity data published. Sabin produced doses staged for emergency deployment to the 2022-2023 Uganda Mubende SUDV outbreak; the outbreak resolved before randomised efficacy data could be collected.
Mechanism. Recombinant vesicular stomatitis virus (rVSV) platform analogous to Ervebo, expressing the Sudan ebolavirus glycoprotein in place of Zaire. Single dose under investigation.
Where it stands. In Phase 1/2 trials. Candidate is part of the WHO Solidarity Trial framework that would deploy multiple SUDV vaccine candidates head-to-head during an outbreak.
Bavarian Nordic + Janssen · Targets EBOV, SUDV, MARV
Mechanism. Modified vaccinia Ankara (MVA-BN) vector encoding glycoproteins from multiple filoviruses. Currently fielded as the Mvabea boost component of the approved Zabdeno + Mvabea Zaire vaccine, but also under study as a standalone heterologous boost or multivalent product.
Where it stands. Multivalent filovirus candidate. Has shown immunogenicity across multiple ebolavirus species in Phase 1 and 2 studies. Not licensed as a standalone product.
Primary sources: ClinicalTrials.gov registration records, WHO R&D Blueprint product profiles, NIAID and Sabin Vaccine Institute disclosures, Bavarian Nordic and IAVI investor releases. We do not consider press releases alone authoritative; where possible, the trial registration is the canonical source.